- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00544856
Effects of a Complex Cognitive Training in Mild Cognitive Impairment and Mild Alzheimer's Disease
A recent meta-analysis that included over 29.000 individuals found that the odds ratio (OR) of individuals with high brain reserve compared to low was 0.54 (p < 0.0001), a risk decrease of 46%. Among the factors that influence cognitive reserve, mentally stimulating activities was the most robust factor after controlling for education, age, occupation and other potential confounds. The brain reserve effect was sustained over a median longitudinal follow-up of 7 years. It would be interesting to detect whether a complex cognitive training could show similar effects on the cognitive abilities of patients with mild Alzheimer's disease (AD) and mild cognitive impairment (MCI) as it has been reported in previous studies based on mentally stimulating activities analysis.
The hypothesis is that a complex cognitive training alters the neural networks in both subject groups and this alteration is associated with improvement or stabilization of cognitive and non-cognitive function.
The investigator will perform a complex cognitive training program. Twenty patients with mild AD and twenty four patients with MCI will be recruited in this study. The patients will be randomised in control- and treatment groups.Additionally indirect effects on non-cognitive functions will be evaluated in caregivers of the patients.
The investigators expect that the cognitive and non-cognitive abilities will be changed during the cognitive training. The investigators also expect differences between treatment and control groups.
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Studietype
Registrering
Fase
- Ikke aktuelt
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Male or female patients aged ≥ 55 years, fulfilling criteria of the National Institute of Neurological and Communicative Disease and Stroke (NINCDS) and the Alzheimer's Disease and Related Disorders Association (ADRDA) for the diagnosis of clinically probable AD or Petersen's criteria of mild cognitive impairment (MCI)
- No evidence for other psychiatric axis I disorders according to DSM-IV criteria
- No uncontrolled arterial hypertension or diabetes mellitus
- No history of drug/alcohol abuse
- Cholinesterase inhibitors or Memantine must have been in a stabile doses at least 2 moths in AD subject group prior to the Baseline
- The patient is able to provide written informed consent to participate in the study. If, at investigator's discretion, a patient is considered not to be capable to give legal consent, then written consent must also be obtained from the patient's legally acceptable representative.
Exclusion Criteria:
- Evidence for other psychiatric axis I disorders according to DSM-IV criteria
- Uncontrolled arterial hypertension or diabetes mellitus
- History of drug/alcohol abuse
- No ability to participate and no willing to give informed consent and comply with the study restrictions
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
|---|---|
|
Placebo komparator: 2
|
|
|
Eksperimentell: 1
cognitive intervention
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
cognition: MMSE, ADAS-cog.
Tidsramme: month 0, 6, 12
|
month 0, 6, 12
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
quality of life
Tidsramme: month 0, 6, 12
|
month 0, 6, 12
|
Samarbeidspartnere og etterforskere
Etterforskere
- Studiestol: Harald Hampel, MD, Department of Psychiatry, Ludwig-Maximilian University, Munich Germany
Publikasjoner og nyttige lenker
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- cogT001
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Kognitiv svikt
-
Uskudar UniversityRekrutteringAMCI - Amnestic Mild Cognitive ImpairmentTyrkia (Türkiye)
-
IRCCS San RaffaeleRekrutteringAlzheimers sykdom | MCI | AMCI - Amnestic Mild Cognitive Impairment | MCI-konvertering til demensItalia
-
Johns Hopkins UniversityNational Institute on Aging (NIA)RekrutteringSøvnforstyrrelser | AMCI - Amnestic Mild Cognitive ImpairmentForente stater
-
IRCCS San RaffaeleAktiv, ikke rekrutterendeMild kognitiv svikt (MCI) | Nevrodegenerativ sykdom | Nevrodegenerativ demens | AMCI - Amnestic Mild Cognitive ImpairmentItalia
Kliniske studier på complex cognitive training
-
Assistance Publique - Hôpitaux de ParisURC-CIC Paris Descartes Necker CochinFullførtArvelig epidermolysis BullosaFrankrike
-
Hacettepe UniversityPåmelding etter invitasjonMotorisk aktivitet | Eksekutiv dysfunksjon | Kognitiv orienteringTyrkia
-
SeppicFullført
-
SeppicFullførtFriske FrivilligeItalia
-
University of BeykentMaltepe UniversityHar ikke rekruttert ennåBærekraft | Klima forandringer | Helsepersonell
-
University of California, Los AngelesRekrutteringKronisk sykdomForente stater
-
Seton Healthcare FamilyUniversity of Texas at AustinFullførtLivskvalitet | Kronisk sykdom | Kronisk sykdomForente stater
-
Roswell Park Cancer InstituteIncuronAvsluttetKlinisk stadium III kutant melanom AJCC v8 | Patologisk stadium IIIB kutant melanom AJCC v8 | Patologisk stadium IIIC kutant melanom AJCC v8 | Klinisk stadium IV kutant melanom AJCC v8 | Patologisk stadium IV kutant melanom AJCC v8 | Stage III bløtvevssarkom i stammen og ekstremiteter AJCC v8 | Stage... og andre forholdForente stater
-
SeppicFullført
-
Massachusetts General HospitalRekrutteringPsykotiske lidelser | Stemningsforstyrrelser | AngstlidelserForente stater